G. Cammarota

Sort by:

Physiologic response to varying levels of pressure support and neurally adjusted ventilatory assist in patients with acute respiratory failure

Davide Colombo, G. Cammarota, Valentina Bergamaschi, Marta De Lucia, Francesco Della Corte, Paolo Navalesi
Intensive Care Medicine
2008

Neurally adjusted ventilatory assist (NAVA) is a new mode wherein the assistance is provided in proportion to diaphragm electrical activity (EAdi). We assessed the physiologic response to varying… (More)

Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.

G. Cammarota, Loredana Masucci, +5 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2015

BACKGROUND Faecal microbiota transplantation (FMT) from healthy donors is considered an effective treatment against recurrent Clostridium difficile infection. AIM To study the effect of FMT via… (More)

A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.

Filippo Canducci, Alessandro Armuzzi, +5 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2000

BACKGROUND Acid suppression plus two antibiotics is considered the reference anti-Helicobacter pylori treatment. Reported eradication rates are around 65-80%. Human Lactobacillus acidophilus shows an… (More)

Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B.

Mauro Pistello, G. Cammarota, +4 authors Mauro Bendinelli
The Journal of general virology
1997

The genetic diversity of 32 Italian isolates of feline immunodeficiency virus (FIV) was studied. Isolates were obtained from domestic cats living in different areas. Sequence data were obtained from… (More)

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

Andrea Lupascu, Mário Francisco Real Gabrielli, +8 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2005

BACKGROUND Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome… (More)

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.

Eleonora Scarpellini, Mário Francisco Real Gabrielli, +6 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2007

BACKGROUND Rifaximin is a broad spectrum non-absorbable antibiotic used for treatment of small intestinal bacterial overgrowth. Doses of 1200 mg/day showed a decontamination rate of 60% with low… (More)

Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.

Enrico Celestino Nista, Marco Candelli, +6 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2004

BACKGROUND Helicobacter pylori eradication fails in about 10% of patients, particularly because of the occurrence of resistance to antibiotics and side-effects. During anti-H. pylori therapy,… (More)

Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma.

F. Maggi, Cinzia Fornai, +8 authors Mauro Bendinelli
The Journal of general virology
1997

Hepatitis C virus (HCV) exists in vivo as a highly variable mixture of closely related genomes (quasispecies), but the pathogenetic significance of such heterogeneity is still largely unknown. To… (More)

Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.

Alessandro Armuzzi, Filippo Cremonini, +9 authors A Gasbarrini
Digestion
2001

BACKGROUND One-week triple therapy is currently regarded as the reference of anti-Helicobacter pylori treatment. However, antibiotic-associated gastrointestinal side effects are among the major… (More)

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

G. Nucera, Mário Francisco Real Gabrielli, +8 authors A Gasbarrini
Alimentary pharmacology & therapeutics
2005

BACKGROUND Small intestinal bacterial overgrowth and sugar malabsorption (lactose, fructose, sorbitol) may play a role in irritable bowel syndrome. The lactulose breath test is a reliable and… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences